Kirn David sold 58,333 shares of 4D Molecular Therapeutics at $13.90 per share, a transaction equal to about 7.1% of the prior holding. Investors can see that 767,486 shares remained in the reported position after the sale, while transaction code S classifies the activity as an open-market sale.

Key Highlights

  • Kirn David held 767,486 4D Molecular Therapeutics shares after the transaction.
  • The sale represented about 7.1% of Kirn David’s prior shareholding.
  • Transaction code S identifies the activity as an open-market sale dated 14 September 2026.

Kirn David sold 58,333 shares of 4D Molecular Therapeutics at $13.90 per share. The transaction involved the company’s stock and reduced the reported position while leaving a substantial holding in place.

Sale Details and Remaining Holding

The transaction date was 14 September 2026. The reported transaction code was S, which denotes an open-market sale in the Form 4 classification system. After the sale, Kirn David owned 767,486 shares of 4D Molecular Therapeutics. The transaction was recorded in connection with Kirn David’s position in the company. The sale was measured against the shares held before the transaction. That comparison puts the transaction at about 7.1% of Kirn David’s prior shareholding.